Loading
Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours.
James Yao was principal investigator of RADIANT-3 and RADIANT-4, which established everolimus for progressive pancreatic and then non-functional lung and GI neuroendocrine tumours, and authored the SEER analysis that documented the rising incidence of NETs. He chairs GI medical oncology at MD Anderson and co-led the NET Task Force of the NCI GI steering committee.
Shares Neuroendocrine tumours and the tags neuroendocrine, trialist.
Shares Neuroendocrine tumours and the tags neuroendocrine, trialist.
Shares MD Anderson Cancer Center and the tag trialist.
Shares Small-molecule kinase inhibitors and the tag trialist.
Shares MD Anderson Cancer Center, Small-molecule kinase inhibitors.
Shares MD Anderson Cancer Center and the tag trialist.
Shares Neuroendocrine tumours and the tag trialist.
Shares MD Anderson Cancer Center and the tag trialist.